Melanoma and Skin Cancer Trials is pleased to announce the appointment of Cheryl-Ann Hawkins as Chief Executive.
With decades of experience in clinical trials, Cheryl-Ann enters the organisation with a proven track record of developing and managing successful teams and delivering measurable and practice-changing outcomes.
Over her decorated 30-year career, Cheryl-Ann has held several senior oncology nursing roles. Her extensive experience in clinical trials has focussed predominantly on early phase oncology trials that aim to ensure cancer patients have access to truly world-class treatments.
“It’s an honour to join the MASC Trials team and spearhead the important, practice changing work being carried out by our investigators,” Cheryl-Ann says.
“Having worked in this area extensively and seen first-hand the impact clinical trials can have on patients and their families, I’m truly humbled by, and excited for, this opportunity.
“I have long been a proponent of the power of collaboration and innovation – two principals that sit at the heart of MASC Trials and its approach to clinical trials. I look forward to continuing the work of my predecessors in improving the prevention, screening, diagnosis and treatment of melanoma and skin cancer.”
The MASC Trials Board would like to thank outgoing CEO, Aileen Boyd-Squires, and wish her all the best for her future endeavours.